Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
AbbVie
Institute of Hematology & Blood Diseases Hospital, China
University of Alabama at Birmingham
University of Utah
European Myeloma Network B.V.
University of Utah
UNC Lineberger Comprehensive Cancer Center
Thomas Jefferson University
University of Washington
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Tongji Hospital
Nanjing IASO Biotechnology Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Olavs Hospital
Shanghai Changzheng Hospital
Peking University People's Hospital
Mayo Clinic
Masonic Cancer Center, University of Minnesota
The First Affiliated Hospital of Soochow University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Peking University First Hospital
OHSU Knight Cancer Institute
Pfizer
Array BioPharma
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
City of Hope Medical Center
H. Lee Moffitt Cancer Center and Research Institute
University of Michigan Rogel Cancer Center
Senesco Technologies, Inc.
IRCCS Centro di Riferimento Oncologico della Basilicata
Clinical Service, China